Karyopharm Therapeutics
KPTI
KPTI
117 hedge funds and large institutions have $64.2M invested in Karyopharm Therapeutics in 2023 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 25 increasing their positions, 41 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
117
Holders Change
-1
Holders Change %
-0.85%
% of All Funds
1.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
25
Reduced
41
Closed
23
Calls
$456K
Puts
$26K
Net Calls
+$430K
Net Calls Change
-$173K
Top Buyers
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.53M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.44M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.1M |
| 4 |
Renaissance Technologies
New York
|
+$1.07M |
| 5 |
Morgan Stanley
New York
|
+$559K |
Top Sellers
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$2.38M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$1.87M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.79M |
| 4 |
BlackRock
New York
|
-$878K |
| 5 |
PL
Parkwood LLC
Cleveland,
Ohio
|
-$661K |
